Gynecologic oncology in 2024:breakthrough trials and evolving treatment strategies for cervical, uterine corpus, and ovarian cancers
- Author:
Sung Jong LEE
1
;
Ji Geun YOO
;
Jin Hwi KIM
;
Jeong-Yeol PARK
;
Jung-Yun LEE
;
Yoo-Young LEE
;
Dong Hoon SUH
Author Information
- Publication Type:Review Article
- From:Journal of Gynecologic Oncology 2025;36(1):e72-
- CountryRepublic of Korea
- Language:English
- Abstract: This review summarized the results of clinical trials in 2024 that were believed to have a significant impact on clinical practice in the field of gynecologic oncology. The SHAPE trial, INTERLACE and KEYNOTE-A18 trials, and BEATcc and COMPASSION-16 trials were included in early-stage, locally advanced, and recurrent/metastatic cervical cancer, respectively. For uterine corpus cancer, updated survival data of the four trials (NRG-GY018, RUBY, AtTEnd, DUO-E) for endometrial cancer and the first survival data of LMS-04 trial for leiomyosarcoma were described. For ovarian cancer, the final overall survival results of PRIMA study were followed by DUO-O, ATHENA-combo, and FIRST-ENGOT-OV44 trial in different disease conditions. Finally, the results of DESTINY-PanTumor02, a basket trial of trastuzumab deruxtecan, were briefly addressed.
